Market Overview

Benzinga's Volume Movers

Related XOOM
Benzinga's Top Initiations
First Analysis Initiates Xoom At Overweight
Related GALT
Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clincial Trial of GR-MD-02 in Combo with Ipilimumab in Metastatic Melanoma
Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement

Xoom (NASDAQ: XOOM) shares moved up 3.75% to $31.83. The volume of Xoom shares traded was 1988% higher than normal. Xoom priced its follow-on offering of 4,403,270 shares of its common stock at a price of $30.50 per share.

Galectin Therapeutics (NASDAQ: GALT) shares rose 23.52% to $10.59. The volume of Galectin Therapeutics shares traded was 760% higher than normal. Galectin Therapeutics received US Patent for the potential treatment for fatty liver disease.

Lannett Company (NYSE: LCI) shares climbed 5.03% to $16.49. The volume of Lannett shares traded was 669% higher than normal. Lannett reported upbeat Q4 results.

SYNNEX (NYSE: SNX) surged 19.39% to $57.27. The volume of SYNNEX shares traded was 489% higher than normal. SYNNEX announced its plans to buy IBM's customer care unit for $505 million.

Posted-In: volume moversNews Intraday Update Markets Movers

 

Most Popular

Related Articles (LCI + GALT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters